Plain-English translation of NCT04665947 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This early-stage trial is testing a new approach called a 'theranostic pair' — two connected tools that work together for pancreatic cancer. First, a special imaging scan using a substance called [68Ga]Ga DOTA-5G helps doctors see if your tumor is a good match for treatment. If it is, you may then receive the treatment medication [177Lu]Lu DOTA-ABM-5G, which is designed to find and attack cancer cells. The goal is to find the safest and most effective dose of this medication for future patients.
Pancreatic cancer is difficult to treat, and most patients need new options after standard chemotherapy stops working. This medication represents a novel approach — it combines diagnostic imaging with targeted therapy — and this is the first time it's being tested in humans to see if it is safe and effective.
You likely qualify if…
You likely don't qualify if…
First, you will have a special PET/CT imaging scan using the diagnostic agent to confirm your cancer is suitable for treatment. If the scan shows your tumor responds to the imaging agent, you may then receive doses of the treatment medication. The study uses a careful dose-escalation approach, meaning small groups of patients receive increasing doses to find the safest level. You will be monitored closely for side effects and how well the treatment is working through blood tests and imaging scans over time.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States